Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control cannot be achieved with monotherapy:
When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions associated with metformin.
In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the previous doses of dapagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because any change may result in alterations in glycemic control, any change in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet.
Renal impairment
No dosage adjustment is necessary in patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Elderly patients
Since metformin is excreted through the kidneys and renal function is likely to decline in elderly patients, this medicine should be used with caution with increasing age (see Precautions for Use, 9. Administration to Elderly Patients).
Improves glycemic control in adults with type 2 diabetes mellitus
Type 2 diabetes
abnormal blood sugar control
cardiovascular disease
cardiovascular risk factors
View approved original textHide original text
This medication is used in conjunction with diet and exercise therapy to help control blood sugar levels in adult patients with type 2 diabetes. Specifically, it helps effectively manage blood sugar levels by combining dapagliflozin and metformin. It is important to consult a specialist regarding the cardiovascular effects associated with dapagliflozin in patients who have difficulty controlling blood sugar and have cardiovascular disease or risk factors. This medication significantly aids in diabetes management alongside overall blood sugar improvement.
How to take
Adult dose
The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control cannot be achieved with monotherapy:
When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions associated with metformin.
In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the previous doses of dapagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because any change may result in alterations in glycemic control, any change in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet.
Renal impairment
No dosage adjustment is necessary in patients with mild renal impairment.
For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Elderly patients
Since metformin is excreted through the kidneys and renal function is likely to decline in elderly patients, this medicine should be used with caution with increasing age (see Precautions for Use, 9. Administration to Elderly Patients).
Precautions
This medication is used for the treatment of diabetes and should not be used in patients with impaired renal function or acute illnesses.
It is not recommended for patients with moderate or worse renal function, and regular renal function tests should be conducted if renal function declines.
During treatment, symptoms of decreased fluid volume or hypotension may occur, so caution is necessary, especially for elderly patients or those taking diuretics.
When used with insulin or sulfonylurea medications, the risk of hypoglycemia may increase; therefore, dosage adjustments may be necessary.
This medication may increase the risk of genital and urinary tract infections, so you should consult a doctor immediately if any infection symptoms appear.
There is a rare but serious side effect of lactic acidosis that can occur, so seek immediate treatment if symptoms such as muscle pain, difficulty breathing, or abdominal pain appear.
Women who are pregnant or breastfeeding should not use this medication, and those planning to become pregnant should consult a healthcare professional.
Excessive alcohol consumption should be avoided while taking this medication; it may be necessary to discontinue it for a certain period prior to surgery or radioiodine imaging.
Vitamin B12 deficiency may occur, so regular monitoring of serum vitamin B12 levels is advisable for long-term users.
In case of overdose, seek medical attention immediately for proper treatment, and dialysis may be necessary.
The safety and efficacy of this medication in children have not been established, and it should be used with caution in elderly patients considering the potential for decreased renal function.
Dizziness or symptoms of hypoglycemia may occur during use, so caution is advised when driving or operating machinery.
This medication should be stored in its original container and kept out of reach of children.
Not everyone experiences these, and they can vary from person to person.
Storage
Store this medication in a tightly sealed container to prevent air or moisture exposure. Additionally, avoid excessively hot or cold places, and it is advisable to store it at room temperature between 1°C and 30°C.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.